Home Tags Ado-trastuzumab emtansine

Tag: ado-trastuzumab emtansine

Bridging HER2 and Prolactin Receptor Improves Efficacy of an HER2 ADCs.

Authors: Andreev J, Thambi N, Perez Bay AE, Delfino FJ, Martin JH, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D,...

Improving Outcomes in the Treatment of Breast Cancer (Video)

Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.The development of these promising new therapeutic agents...

A Call to Action: Submit Your Expertise

Valuable lessons learned from both approved antibody-drug conjugates  (brentuximab vedotin /Adcetris®; Seattle Genetics approved in 2011 and ado-trastuzumab emtansine or T-DM-1/Kadcyla® approved in 2013)...

Phase I Study Shows Daichi Sankyo’s Anti-HER2 Antibody-drug Conjugate DS-8201a to...

Safety and preliminary efficacy data from a phase I study of DS-8201a (Daiichi Sankyo Company), a novel investigational HER2-targeting antibody drug conjugate or ADC,...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...

Growing Drug Development Outsourcing Expected to Increase Demand for Antibody-drug Conjugates

A recent research report published by Technavio, a leading global technology research and advisory company, confirms that the global antibody-drug conjugates (ADC) market will grow...

Presurgery Combination of Trastuzumab Emtansine + Pertuzumab May Improve Outcomes of...

The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...

Synaffix’s New High Potency Lab now Fully Operational to Support Growing...

Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...

Survival Benefit of Ado-trastuzumab Emtansine in Heavily Pretreated HER2+ Breast Cancer...

Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium (SABCS) held in San Antonio in December...